$RKLB

Cathie Wood’s ARK sells Alphabet stock, buys Rocket Lab

ARK ETFs sold 16,422 Alphabet (GOOGL) shares for $5.8M, bought 359,612 Rocket Lab (RKLB) shares for $25.1M. Also reduced Twist Bioscience (TWST) and 10X Genomics (TXG) positions, while increasing stakes in Scribe Therapeutics (SCTX), Veracyte (VCYT), and Beam Therapeutics (BEAM).

Original reporting
Published Sep 23, 2026, 12:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 1:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RKLB
Bullish
medium confidence
Mentioned
$RKLB · $GOOGL · $TWST · $TXG · $SCTX · $VCYT
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RKLBBullishLow
01

Why it matters

The trades suggest a strategic pivot toward space and biotech, possibly anticipating sector tailwinds.

02

Market read

Fund activity can move small- to mid-cap stocks; ARK's sizable purchases may influence price dynamics.

03

What to watch

Potential upcoming regulatory scrutiny on big tech could be driving the Alphabet sell.

Relevance 5/10Novelty 5/10Timing: today

Background

ARK's daily trade disclosures provide insight into its evolving portfolio allocations.

Company-level read

Ticker impact

$RKLBBullishMedium confidence
Context

ARK purchased 359,612 shares of Rocket Lab, a $25.1M investment, indicating increased exposure.

Expected impact

moderate upside pressure

Evidence & confidence

Large fund buy suggests confidence in growth prospects.

$GOOGLBearishLow confidence
Context

ARK sold 16,422 shares of Alphabet, a $5.8M divestiture, reducing exposure.

Expected impact

slight downside risk

Evidence & confidence

Sell size modest relative to market cap.

$TWSTNeutralLow confidence
Context

ARK sold 21,335 shares of Twist Bioscience, a $3.5M reduction.

Expected impact

minimal effect

Evidence & confidence

Sell amount small relative to float.

$TXGNeutralLow confidence
Context

ARK sold 49,651 shares of 10X Genomics, a $3.9M divestiture.

Expected impact

minimal impact

Evidence & confidence

Sell size modest.

$SCTXBullishMedium confidence
Context

ARK bought 88,323 shares of Scribe Therapeutics, a $2.5M investment.

Expected impact

potential upside

Evidence & confidence

Fund accumulation indicates confidence.

$VCYTBullishLow confidence
Context

ARK bought 12,583 shares of Veracyte, a $0.5M purchase.

Expected impact

slight upside

Evidence & confidence

Purchase size relatively small.

$BEAMBullishLow confidence
Context

ARK bought 9,519 shares of Beam Therapeutics, a $0.24M purchase.

Expected impact

limited upside

Evidence & confidence

Very small trade size.

$PNeutralLow confidence
Context

ARK sold 19,139 shares of Everpure, a $2.2M divestiture.

Expected impact

minimal effect

Evidence & confidence

Trade size modest relative to market.

Market effects

Increased focus on space launch and biotech sectors from ARK's reallocation.

US market exposure shifts modestly toward growth-oriented biotech and aerospace firms.

Limited global impact; primarily influences US-listed growth stocks.

Counterpoint

ARK's reduction in Alphabet may signal overvaluation concerns despite broader tech strength.

Key entities

  • Cathie Wood

    Founder of ARK Invest, guiding fund strategy.

  • ARK Invest

    Active manager of thematic ETFs.

Related articles

$RKLBHighAI 8/10

Rocket Lab CEO Puts Iridium Deal Alongside SpaceX And Amazon’s Spectrum Bets: ‘You Can’t Just Magic Up Spectrum’

Rocket Lab (RKLB) CEO Peter Beck highlighted the value of Iridium's (IRDM) spectrum in an interview, comparing it to investments by SpaceX and Amazon. RKLB stock rose 3% to $71.98. Beck estimated Rocket Lab could have built Iridium's constellation for $350M, much less than Iridium's $3B estimate. Shareholders will vote on the merger Thursday. Rocket Lab also secured $1.944B for the acquisition. Additionally, RKLB is working on a Space Force project with a $397M contract.

$GOOGLMed

Alphabet, Insurers to Contest Social Media Dispute in California

Alphabet Inc. and its units Google and YouTube won a Delaware court ruling to proceed with a California lawsuit against AIG insurers over social media addiction claims. The court deferred to California as the first-filed venue, pausing AIG's parallel Delaware case. Alphabet seeks coverage for defending lawsuits alleging harm from social media. AIG had not issued a coverage decision by February 2026, leading to Alphabet's lawsuit.

$RKLBMedAI 8/10

Why Rocket Lab Is Up Today

Rocket Lab shares rose 2% on defense awards, satellite work, and financing for its Iridium acquisition. The company secured $1.94B via share sale, replacing a $3.6B debt facility. It won $190M and $266M contracts from the U.S. government and Viasat. Raymond James initiated coverage with an $80 price target, expecting positive EBITDA and free cash flow by 2027-2028.

$RKLBMed

SpaceX Winds Down Falcon 9 As Rocket Lab Eyes Gap - Rocket Lab (NASDAQ:RKLB)

SpaceX (SPCX) is phasing out Falcon 9, focusing on Starship, and stopping new shared mission sales. Falcon 9's launch price rose 19% to $74M over five years. Rocket Lab (RKLB) sees an opportunity with its Neutron rocket, targeting 13-ton payloads. Rocket Lab's backlog exceeds 90 missions, and it aims to acquire Iridium (IRDM) for $8B, adding a satellite network. Neutron's 2026 launch probability is 9%, per Polymarket.

$RKLBHighAI 9/10

Rocket Lab's SpaceX Playbook: Own the Rocket, Constellation and Customer

Rocket Lab (RKLB) is expanding beyond rockets, acquiring Iridium (IRDM) for $8B to integrate launch, spacecraft, and services, similar to SpaceX's model. The deal adds Iridium's 66-satellite network and 2.5M subscribers. Rocket Lab aims to streamline operations and increase revenue, with Iridium generating $871.7M in 2025 vs. Rocket Lab's $602M. Key catalysts include FCC approval and Neutron's 2026 debut.